-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Targeting the Tumor Microenvironment in Lymphoid Malignancies

PhD Trainee
Sponsor: Scientific Committee on Lymphoid Neoplasia
Program: Scientific Program
Saturday, December 5, 2015: 2:00 PM-3:30 PM
Valencia D (W415D), Level 4 (Orange County Convention Center)
Sunday, December 6, 2015: 9:30 AM-11:00 AM
Valencia BC (W415BC), Level 4 (Orange County Convention Center)

Description:

This session will address the role the tumor microenvironment plays in lymphoid malignancies and how disrupting the pro-tumorigenic niche (or microenvironment) including the immune checkpoint network provides a new weapon against cancer. Recent translational discoveries with checkpoint inhibitors have the potential to unleash anti-tumor immunity in populations (or subsets) of patients with lymphoid malignancies.

Dr. Steidl will give an overview on the tumor microenvironment and present his data on biomarkers and acquired immune privilege.

Dr. Ramsay will discuss immune checkpoint signalling axes including PD-L1, CTLA-4 in the tumor microenvironment and related immune evasion mechanisms.

Dr. Ansell will focus on clinical trial results with PD-1 and CTLA4 directed antibodies in non-Hodgkin lymphoma and Hodgkin’s disease.

Chair:
Angela Dispenzieri, MD, Mayo Clinic

Disclosures:
No relevant conflicts of interest to declare.

Christian Steidl, MD

Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada

Alan G. Ramsay, PhD

Department of Haemato-Oncology, King’s College London, London, United Kingdom

Stephen Ansell, MD, PhD

Mayo Clinic, Rochester, MN

See more of: Scientific Program